Cargando…

Vedolizumab blocks α4β7 integrin-mediated T cell adhesion to MAdCAM-1 in microscopic colitis

BACKGROUND: In Crohn’s disease and ulcerative colitis, the anti-α4β7 integrin antibody vedolizumab has demonstrated efficacy in phase III trials and has been successfully used under real-world conditions. Occasionally, it has also been used in other forms of inflammatory bowel disease (IBD) such as...

Descripción completa

Detalles Bibliográficos
Autores principales:	Besendorf, Laura, Müller, Tanja M., Geppert, Carol-Immanuel, Schneider, Ines, Mühl, Laura, Atreya, Imke, Vitali, Francesco, Atreya, Raja, Neurath, Markus F., Zundler, Sebastian
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	SAGE Publications 2022
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9244938/ https://www.ncbi.nlm.nih.gov/pubmed/35784193 http://dx.doi.org/10.1177/17562848221098899

Ejemplares similares

α4β7 integrin-dependent adhesion of T cells to MAdCAM-1 is blocked by vedolizumab in patients with chronic refractory pouchitis
por: Melde, Michaela, et al.
Publicado: (2021)

Baseline levels of dynamic CD4(+) T cell adhesion to MAdCAM-1 correlate with clinical response to vedolizumab treatment in ulcerative colitis: a cohort study
por: Allner, Clarissa, et al.
Publicado: (2020)

Clinical Response to Vedolizumab in Ulcerative Colitis Patients Is Associated with Changes in Integrin Expression Profiles
por: Fuchs, Friederike, et al.
Publicado: (2017)

Clinical experiences and predictors of success of treatment with vedolizumab in IBD patients: a cohort study
por: Mühl, Laura, et al.
Publicado: (2021)

Limited Dose-Dependent Effects of Vedolizumab on Various Leukocyte Subsets
por: Becker, Emily, et al.
Publicado: (2022)

MAdCAM costimulation through Integrin-α(4)β(7) promotes HIV replication
por: Nawaz, Fatima, et al.
Publicado: (2018)

The Force-Dependent Mechanism of an Integrin α4β7–MAdCAM-1 Interaction
por: Su, Youmin, et al.
Publicado: (2023)

Development of Mucosal PNAd(+) and MAdCAM-1(+) Venules during Disease Course in Ulcerative Colitis
por: Roosenboom, Britt, et al.
Publicado: (2020)

Effects of Anti-Integrin Treatment With Vedolizumab on Immune Pathways and Cytokines in Inflammatory Bowel Diseases
por: Rath, Timo, et al.
Publicado: (2018)

Bile Acids Modulate Colonic MAdCAM-1 Expression in a Murine Model of Combined Cholestasis and Colitis
por: Gao, Rachel Y., et al.
Publicado: (2020)

Antibody secreting cells are critically dependent on integrin α4β7/MAdCAM-1 for intestinal recruitment and control of the microbiota during chronic colitis
por: Tyler, Christopher J., et al.
Publicado: (2021)

Healing of the epithelial barrier in the ileum is superior to endoscopic and histologic remission for predicting major adverse outcomes in ulcerative colitis
por: Rath, Timo, et al.
Publicado: (2023)

Bile acids regulate MAdCAM-1 expression to link the gut microbiota to cancer immunosurveillance
por: Fidelle, Marine, et al.
Publicado: (2023)

Case Report: IBD-like colitis following CAR T cell therapy for diffuse large B cell lymphoma
por: Zundler, Sebastian, et al.
Publicado: (2023)

MAdCAM-1/α4β7 Integrin-Mediated Lymphocyte/Endothelium Interactions Exacerbate Acute Immune-Mediated Hepatitis in Mice
por: Schippers, Angela, et al.
Publicado: (2020)

Force-Regulated Calcium Signaling of Lymphoid Cell RPMI 8226 Mediated by Integrin α(4)β(7)/MAdCAM-1 in Flow
por: Sun, Dongshan, et al.
Publicado: (2023)

TNF-α induced endothelial MAdCAM-1 expression is regulated by exogenous, not endogenous nitric oxide
por: Oshima, Tadayuki, et al.
Publicado: (2001)

MAdCAM-1-Mediated Intestinal Lymphocyte Homing Is Critical for the Development of Active Experimental Autoimmune Encephalomyelitis
por: Kuhbandner, Kristina, et al.
Publicado: (2019)

Protective effect of the novel calcineurin inhibitor voclosporin in experimental colitis
por: Lindemann, Aylin, et al.
Publicado: (2023)

Melatonin reduces TNF-a induced expression of MAdCAM-1 via inhibition of NF-kB.
por: Sasaki, Makoto, et al.
Publicado: (2002)

Circulating MAdCAM-1 and ITGB7 in Patients with Plaque Psoriasis and Eruptive Lichen Planus—Preliminary Data
por: Baran, Anna, et al.
Publicado: (2021)

Extent of Mucosal Inflammation in Ulcerative Colitis Influences the Clinical Remission Induced by Vedolizumab
por: Scarozza, Patrizio, et al.
Publicado: (2020)

Anti‐β7 integrin treatment impedes the recruitment on non‐classical monocytes to the gut and delays macrophage‐mediated intestinal wound healing
por: Sommer, Katrin, et al.
Publicado: (2023)

Inflammatory cytokines induce MAdCAM-1 in murine hepatic endothelial cells and mediate alpha-4 beta-7 integrin dependent lymphocyte endothelial adhesion In Vitro
por: Ando, Tomoaki, et al.
Publicado: (2007)

Involvement of oxidative stress and mucosal addressin cell adhesion molecule-1 (MAdCAM-1) in inflammatory bowel disease
por: Tanida, Satoshi, et al.
Publicado: (2011)

Phase II evaluation of anti-MAdCAM antibody PF-00547659 in the treatment of Crohn’s disease: report of the OPERA study
por: Sandborn, William J, et al.
Publicado: (2018)

Anti-MAdCAM-1-Conjugated Nanocarriers Delivering Quantum Dots Enable Specific Imaging of Inflammatory Bowel Disease
por: Truffi, Marta, et al.
Publicado: (2020)

Functional Molecular Network Analysis Enables Prediction of Response to Vedolizumab Therapy in Anti-TNF Refractory IBD Patients
por: Breidert, Matthias, et al.
Publicado: (2020)

Long-term Safety and Efficacy of the Anti-MAdCAM-1 Monoclonal Antibody Ontamalimab [SHP647] for the Treatment of Ulcerative Colitis: The Open-label Study TURANDOT II
por: Reinisch, Walter, et al.
Publicado: (2021)

Anti-MAdCAM-1 antibody (PF-00547659) for active refractory Crohn’s disease in Japanese and Korean patients: the OPERA study
por: Saruta, Masayuki, et al.
Publicado: (2020)

Increased Motility and Suppression of Ex Vivo–Expanded Regulatory T Cells Designed for Adoptive Transfer Therapy in Ulcerative Colitis
por: Müller, Tanja M., et al.
Publicado: (2023)

A Small Molecule, Which Competes with MAdCAM-1, Activates Integrin α(4)β(7) and Fails to Prevent Mucosal Transmission of SHIV-SF162P3
por: Arrode-Brusés, Géraldine, et al.
Publicado: (2016)

Anti-MAdCAM Antibody Increases ß7+ T Cells and CCR9 Gene Expression in the Peripheral Blood of Patients With Crohn’s Disease
por: Hassan-Zahraee, Mina, et al.
Publicado: (2018)

Correction: A Small Molecule, Which Competes with MAdCAM-1, Activates Integrin α(4)β(7) and Fails to Prevent Mucosal Transmission of SHIV-SF162P3
por: Arrode-Brusés, Géraldine, et al.
Publicado: (2016)

Mild COVID-19 Symptoms in an Infliximab-Treated Ulcerative Colitis Patient: Can Ongoing Anti-TNF Therapy Protect against the Viral Hyperinflammatory Response and Avoid Aggravated Outcomes?
por: Abdullah, Abdullah, et al.
Publicado: (2020)

How the Tumor Micromilieu Modulates the Recruitment and Activation of Colorectal Cancer-Infiltrating Lymphocytes
por: Atreya, Imke, et al.
Publicado: (2022)

Differential effects of α4β7 and GPR15 on homing of effector and regulatory T cells from patients with UC to the inflamed gut in vivo
por: Fischer, Anika, et al.
Publicado: (2016)

The TLR9 Agonist Cobitolimod Induces IL10-Producing Wound Healing Macrophages and Regulatory T Cells in Ulcerative Colitis
por: Schmitt, Heike, et al.
Publicado: (2020)

Transfection of IL-10 expression vectors into endothelial cultures attenuates α4β7-dependent lymphocyte adhesion mediated by MAdCAM-1
por: Sasaki, Makoto, et al.
Publicado: (2003)

Nr4a1-dependent non-classical monocytes are important for macrophage-mediated wound healing in the large intestine
por: Heidbreder, Karin, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_0hphp3c325dddpu56o03nidmqu